<DOC>
	<DOCNO>NCT00073177</DOCNO>
	<brief_summary>The aim study compare effect oral roflumilast placebo lung function patient asthma .</brief_summary>
	<brief_title>Efficacy Safety Roflumilast Patients With Asthma ( BY217/M2-012 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Main Persistent bronchial asthma No change asthma treatment within 4 week prior visit 1 Nonsmoker exsmoker ( 12 month longer ) Main Poorly control asthma seasonal asthma History low airway infection four week prior visit 1 Chronic obstructive pulmonary disease ( COPD ) and/or relevant lung disease Patients use &gt; 8puffs/dayshortacting bronchodilator ( betaagonists ) ( 3 day per week average ) prior visit 1 Clinically relevant abnormal laboratory value suggest undiagnosed disease , severe renal insufficiency , active hepatitis HIV infection Diagnosis , treatment remission cancer ( basal cell carcinoma ) within two year prior visit 1 Patients chronic heart failure Suspected hypersensitivity and/or contraindication roflumilast albuterol/salbutamol Female patient childbearing potential use adequate mean birth control pregnant breastfeeding female Patients receive investigational medication device month prior visit 1 plan use another investigational medication study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>